与多发性骨髓瘤相关的无形性贫血:临床和病理生理学的见解
Tinatin Muradashvili1, Yuxin Liu2, Jennifer VanOudenhove3
1Department of Internal Medicine, Yale School of Medicine, Waterbury, CT, USA.
Leukemia & lymphoma
|September 3, 2024
概括
这项研究探讨了多发性骨髓瘤 (MM) 患者的免疫细胞衰减,这些患者患有无形成性贫血 (AA). 血细胞导向疗法和免疫抑制疗法 (IST) 在这些复杂病例中显示出对细胞衰减的潜在益处.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 多发性骨髓瘤 (MM) 可以出现免疫细胞衰减.
- 在MM患者中同时获得的无形性贫血 (AA) 是罕见的,并带来治疗挑战.
- 了解MM和AA之间的相互作用对于有效管理至关重要.
研究的目的:
- 为了研究MM患者的免疫细胞衰减,同时AA.
- 在这些患者中评估血细胞导向疗法和免疫抑制疗法 (IST) 的疗效.
- 探索MM和AA同时发生的潜在机制.
主要方法:
- 对三例MM临床病例与并发AA的回顾性分析.
- 治疗评估包括血细胞导向疗法和IST.
- 在体外血清测试以评估血小板功能和原始细胞反应.
- 在MM患有AA的患者中分析细胞因子水平 (IL8,IL15).
主要成果:
- 这三位患者在血细胞导向疗法中实现了MM的部分反应.
- 一名患者经历了AA的完全消失;两个患者在输血需求方面出现了部分改善.
- 在两个患有持续严重AA的患者中,IST改善了输血需求.
- 试验室研究显示了血小板线粒体功能障碍和亡,但没有血清特异性抑制红细胞菌落的形成.
- 在AA的MM患者中观察到IL8和IL15水平升高.
结论:
- 血细胞导向疗法可以改善MM,并在并发AA中部分影响细胞衰竭.
- 在MM患者的输血依赖性细胞衰竭管理中,IST是有效的.
- 骨髓瘤相关的免疫调节失调可能会导致T细胞自反应性破坏造血干细胞.
- 升高的IL8和IL15可能在这种共发生的致病性中起作用.
相关概念视频
Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
Bone Marrow Sampling and Transplants
316
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
316
Disorders of Leukocytes
914
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
914
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Erythropoiesis
4.1K
Red blood cells (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
4.1K
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K


